Blood Transfusion Diagnostics Market Share

Blood Transfusion Diagnostics Market Overview

November 2023

Versiti, an organization renowned for its pioneering efforts in blood health innovation, declared today the procurement of Pearl Pathways, a favored collaborator and trusted advisor in the life sciences industry, to facilitate the development of innovative and expedited products.

Pearl Pathways, headquartered in Indianapolis, is a comprehensive life science consulting firm that specializes in delivering specialized CRO services, regulatory affairs, and quality compliance. An additional AHRPP-accredited, independent IRB oversees all facets of human research at Pearl. With regard to life science service providers and biopharmaceutical, medical device, and diagnostic companies, the organization provides comprehensive support in terms of clinical, regulatory, and quality compliance requirements.

"Pearl Pathways brings deep expertise in life science product development, which ultimately leads to getting life-saving devices, diagnostics, and therapeutics to patients faster," said Versiti President and Chief Executive Officer Chris Miskel. "By engaging in this strategic collaboration, Versiti Clinical Trials enhances the range and variety of its research-based solutions while also fortifying its spectrum of capabilities to facilitate earlier disease cures."

By enabling Versiti to assist clinical trials sponsors earlier and further along the development pathway, while continuing to provide services until regulatory approval and commercialization, Pearl Pathways expands the organization's scope.

This transaction further enhances the functionalities established by Versiti's Diagnostic Laboratories. It transpires subsequent to the organization's procurement of Quantigen, a specialized laboratory situated in Fishers, Indiana, and Cenetron Central Laboratories and Salus IRB, both based in Texas, earlier this year.

"The Pearl Pathways staff is ecstatic to announce their entry into Versiti." With the aim of enhancing patient care, Versiti has supported fundamental and translational research for decades. "Pearl and Versiti will work together to accelerate the development of the next generation of therapies and devices," stated Gretchen Bowker, founder of Pearl Pathways.

More than 2,300 individuals are employed by Versiti, which has offices in Wisconsin, Illinois, Indiana, Michigan, Ohio, and Texas, in addition to its Milwaukee headquarters.

Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.

• To provide detailed analysis of the market structure along with forecast for the next seven years of the various segments and sub-segments of the Blood Transfusion Diagnostics market.


• To provide insights about factors affecting the market growth.


• To analyze the Blood Transfusion Diagnostics market based on various factors- Price Analysis, Supply Chain Analysis, Porters’ Five Force Analysis etc.


• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies - Americas, Europe, Asia Pacific and Middle East & Africa and their countries.


• To provide country level analysis of the market with respect to the current market size and future prospective.


• To provide country level analysis of the market for segments by product, by technology, by end and its sub-segments.


• To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Blood Transfusion Diagnostics Market.


• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Blood Transfusion Diagnostics market.

Key Players

• Grifols (Spain)


• Thermo Fisher Scientific, Inc. (U.S.)


• Roche Diagnostics (Switzerland)


• bioMérieux (France)


• Bio-Rad Laboratories Inc. (U.S.)


• Immucor (U.S)


• Siemens Healthineers (Germany)


• Ortho Clinical Diagnostics Inc. (U.S.)


• Becton


• Dickinson and Company (U.S.)


• Novartis AG (Switzerland)


• Beckman Coulter Inc. (U.S.)


• Ortho Clinical Diagnostics (U.S)


• Beckman Coulter (U.S)


• Diagast (France)


• Abbott Diagnostics (U.S)


• BAG healthcare (Germany)


• DiaSorin (Italy)


• Fujirebio (Belgium)


• Grifols (Spain)


• Quidel (U.S)


• Hologic/Gen-Probe (U.S)


• Biokit (Spain)

The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

Blood Transfusion Diagnostics Market Segmentation

Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. 

On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.

Blood Transfusion Diagnostics Market Regional Analysis

Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.

Recent Development 

Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.

Intended Audience

• 
  
  
  
  • Medical device manufactures
  
  
  • Medical devices suppliers
  
  
  • Contract Research Organizations (CROs)
  
  
  • Research and Development (R&D) Companies
  
  
  • Academic Medical Institutes and Universities